6-Bromoindole-3-acetonitrile

CAS No. 152213-61-1

6-Bromoindole-3-acetonitrile( 2-(6-bromo-1H-indol-3-yl)acetonitrile | 6-Bromo-1H-indole-3-acetonitrile | ZINC13379652 )

Catalog No. M29560 CAS No. 152213-61-1

6-Bromoindole-3-acetonitrile is a marine derived natural products found in Pseudosuberites hyalinus.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 Get Quote
10MG 68 Get Quote
25MG 115 Get Quote
50MG 173 Get Quote
100MG 258 Get Quote
200MG 388 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    6-Bromoindole-3-acetonitrile
  • Note
    Research use only, not for human use.
  • Brief Description
    6-Bromoindole-3-acetonitrile is a marine derived natural products found in Pseudosuberites hyalinus.
  • Description
    6-Bromoindole-3-acetonitrile is a marine derived natural products found in Pseudosuberites hyalinus.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    2-(6-bromo-1H-indol-3-yl)acetonitrile | 6-Bromo-1H-indole-3-acetonitrile | ZINC13379652
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    152213-61-1
  • Formula Weight
    235.08
  • Molecular Formula
    C10H7BrN2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N#CCC1=CNC=2C=C(Br)C=CC21
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Scabertopin

    Scabertopin has a significant antitumor effect in vitro in a concentration-dependent manner. It is isolated from the whole plant of Elephantopus scaber.

  • VUF 5574

    human adenosine A3 receptor antagonist.

  • Euchrestaflavanone B

    Euchrestaflavanone B shows antibacterial activity against Gram positive bacteria, Staphylococcus aureus, Bacillus subtilis and Bacillus cereus. Euchrestaflavanone B may function by inhibiting oncogenic disease, at least in part, through the inhibition of protein kinase CKII activity.